GH Secretagogues
Sermorelin
← Back to Library
Limited / unverified Limited / unverified Limited / unverified GH Axis
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 2, 5, 10 mg
Dosing window: Pre-Bed Fasted
Receptor / target: GHRH
Properties: GH Secretagogue
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-16 | 200mcg to 500mcg daily | Administered right before bed. Must be fasted for 2-3 hours prior. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Protocol logic check
Protocol context: GH-axis protocols are not 'more is better.' The logic is pulse quality, recovery time, IGF-1/glucose monitoring, and avoiding receptor desensitization, edema, appetite spikes, numbness, or blood-pressure strain. Entry context: target (GHRH); route Subcutaneous; timing Pre-Bed Fasted. Limited-evidence dosing tables are hypotheses, not recommendations. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. GH-axis stacking should be filtered for total IGF-1/glucose burden, not just expected synergy.
Independent evidence
Independent safety notes: No independent approved-label regimen is listed for this entry. Dosing notes remain unverified.
Regulatory status: no approved label identified
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Active malignancy: GH stimulation may promote tumor growth. Limited / unverified
- History of malignancy: exercise caution; assess risk-benefit before initiating. Limited / unverified
- Active acromegaly or conditions involving GH excess. Limited / unverified
- Concurrent use with CJC-1295 No DAC, CJC-1295 DAC, or tesamorelin: direct GHRH receptor redundancy; do not stack two GHRH analogs. Limited / unverified
- Concurrent use with HGH 191aa: exogenous GH bypasses the pituitary that sermorelin depends on; sermorelin stimulates a pituitary already suppressed by exogenous GH. Limited / unverified
- Disruption of the hypothalamic-pituitary axis: pituitary adenoma, cranial radiation, pituitary surgery, or hypopituitarism. Limited / unverified
- Concomitant high-dose glucocorticoid therapy: suppresses pituitary GH response. Limited / unverified
- Uncontrolled diabetes mellitus or significant insulin resistance: GH elevation worsens glycemic control; monitor fasting glucose. Limited / unverified
- Diabetic ketoacidosis. Limited / unverified
- Pregnancy: safety not established. Limited / unverified
- Breastfeeding: safety not established. Limited / unverified
- Known hypersensitivity to sermorelin acetate or any excipients. Limited / unverified
- Pediatric use in subjects with closed growth plates. Limited / unverified
Side effects (limited evidence)
- Injection site flushing and erythema: the most commonly reported adverse effect; localized redness, warmth, and itching at the injection site within minutes of administration. Limited / unverified
- Mild water retention: GH-mediated sodium and fluid retention; the most conservative profile of all GHRH analogs in this database. Limited / unverified
- Headache: vasodilation from GH pulse; typically mild and transient. Limited / unverified
- Transient facial flushing: immediate post-injection vasodilation. Limited / unverified
- Mild lethargy or fatigue: associated with the GH pulse. Limited / unverified
- Dizziness: transient; post-injection. Limited / unverified
- Nausea: rare at standard doses. Limited / unverified
- Mild joint stiffness: GH-related periarticular fluid; less pronounced than CJC-1295 DAC. Limited / unverified
- Tingling or numbness: mild paresthesia; less common than with longer-acting GHRH analogs. Limited / unverified
- Vivid dreams: GH elevation during nocturnal sleep. Limited / unverified
- Mild transient blood sugar changes: less clinically significant than with tesamorelin or HGH 191aa. Limited / unverified
- Antibody formation: anti-sermorelin antibodies may develop with extended cycles; may reduce efficacy; clinically significant binding capacity is rare. Limited / unverified
- Pituitary downregulation: lower risk than longer-acting GHRH analogs; 4-week washout is adequate for receptor recovery. Limited / unverified
- Injection site pain: mild discomfort at subcutaneous administration site. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations: